Zedira’s general approach in medicine targets dysregulated transglutaminase activity in disease states.
In the human body, eight
transglutaminases fulfill a broad variety of physiological functions. On the other hand,
transglutaminases are involved in the pathophysiology of various disorders.
Celiac disease,
thrombosis, fibrosis or even cancer and such neurodegenerative diseases as Alzheimer’s, Huntington’s and Parkinson’s disease are just some examples.
Celiac DiseaseZedira’s drug candidate ZED1227 targeting dysregulated TG2 in
celiac disease is currently tested in phase 2 clinical trials (proof-of-concept).
read more
Partnering in Drug DevelopmentZedira offers its proprietary drug discovery platform for partnering in drug development
read more
Gluten Sensitive Neurological Disorders Auto-antibodies specific for neuronal transglutaminase (TG6) can be measured with our proprietary ELISA-kits.
New: Analytical service for measurement of TG6-autoantibodies in human serum samples..
read more
Thrombosis / AnticoagulationProof-of-principle for
safe anticoagulation, meaning anticoagulation without increased bleeding risk using blood coagulation factor FXIIIa-blockers has recently been shown.
read more